Olix FY 2025 Annual ReportBeta
Olix annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Olix FY 2025 Annual Report Analysis
Business Overview
- • KRW 14.67B total revenue in FY2025, including KRW 9.61B technology licensing and KRW 5.06B research service sales (new in 2025)
- • Feb 2025 exclusive global license agreement with Eli Lilly for OLX75016 (OLX702A), a GalNAc-asiRNA MASH/obesity drug, total KRW 911.7B
Management Discussion & Analysis
- • Revenue KRW 14.7B (+158.4% YoY); operating loss KRW 30.0B (-3.1%); net loss KRW 15.7B (-61.3%)
- • Equity capital rose to KRW 150.1B (+712.4%) due to convertible preferred stock issuance and convertible bond conversion
Risk Factors
- • USD and EUR FX exposure with 10% rate move causing ±KRW 479M pre-tax profit impact in FY2025, compared to ±KRW 56M in prior year
- • Variable long-term borrowings KRW 21.43B at FY2025-end, with 1% interest rate change impacting pre-tax profit by ±KRW 214.3M
Olix FY 2025 Key Financial MetricsDART
Total Assets
KRW 195.4B
▲ +174.2% YoY
Operating Cash Flow
-KRW 15.9B
▲ +43.3% YoY
Source: KIFRS consolidated financial data from Olix annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding